Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
Status:
Terminated
Trial end date:
2003-11-21
Target enrollment:
Participant gender:
Summary
The major goal of this study is to determine the risks and benefits of stem cell transplants
in combination with a newer, less toxic conditioning chemotherapy treatment in patients with
severe sickle cell disease (SCD) or sickle hemoglobin variants (hemoglobin SC or hemoglobin
SB0/+), or homozygous b0/+ thalassemia or severe B0/+ thalassemia variants. Participation in
this project will be for one year, with follow up evaluations done every 6 months thereafter
for 10 years or until participants are 18 years old.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Texas Children's Hospital The Methodist Hospital Research Institute The Methodist Hospital System